Neoadjuvant and Adjuvant Pembrolizumab in Resectable Locally Advanced, Human Papillomavirus–Unrelated Head and Neck Cancer: A Multicenter, Phase II TrialRavindra Uppaluri, Douglas R. Adkins, Liye Zhou et al.|Clinical Cancer Research|2020Cited by 368
Neoadjuvant and Adjuvant Pembrolizumab in Locally Advanced Head and Neck CancerRavindra Uppaluri, Douglas Adkins, Robert I. Haddad et al.|New England Journal of Medicine|2025Cited by 277
Diagnosis and Management of Squamous Cell Carcinoma of Unknown Primary in the Head and Neck: ASCO GuidelineEllie Maghami, J.J. Caudell, Nofisat Ismaila et al.|Journal of Clinical Oncology|2020Cited by 221
Partial p16 staining in oropharyngeal squamous cell carcinoma: extent and pattern correlate with human papillomavirus RNA statusJames S. Lewis, Samir K. El‐Mofty, Rebecca D. Chernock et al.|Modern Pathology|2012Cited by 129
Preexisting tumor-resident T cells with cytotoxic potential associate with response to neoadjuvant anti–PD-1 in head and neck cancerGiacomo Oliveira, Ravindra Uppaluri, Ann Marie Egloff et al.|Science Immunology|2023Cited by 118